MarginsXMarginsX
Home › Markets › Health Care › VERA

Vera Therapeutics Inc. (VERA)

VERA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$26.97
-4.02% on the day
Market cap
$1.9B
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerVERA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001831828
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
1.8 months
$55.3M cash at September 30, 2026
Share count, 1 year
+13.1%
2025-10-30 to 2026-10-29 · +62.7% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$8.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$55.3M cash; operating cash flow -$94.0M a quarter.Report 2026-09-30
Shares outstanding72,298,770 (2026-10-29); 63,928,066 a year earlier; 44,432,945 three years earlier.Cover page 2026-10-29
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2025-12-10
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, San Francisco, California, United StatesPCAOB Form AP 2026-03-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $250K, sold $9.0M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$10.3M-$93.7M-$99.2M$55.3M$75.4MNeeds four quarters10-Q 2026-11-05
Q2 2026
2026-06-30
Not filed-$109.5M-$100.3M$48.9M$75.2MNeeds four quarters10-Q 2026-11-05
Q1 2026
2026-03-31
Not filed-$121.0M-$106.5M$114.4M$75.0MNeeds four quarters10-Q 2026-11-05
Q4 2025
2025-12-31
Not filed-$91.1M-$70.0M$354.7M$74.8MNeeds four quarters10-K 2026-02-26
Q3 2025
2025-09-30
$0-$80.3M-$61.9M$57.8M$74.6MNeeds four quarters10-Q 2026-11-05
Q2 2025
2025-06-30
Not filed-$76.5M-$54.8M$49.1M$74.5MNeeds four quarters10-Q 2026-11-05
Q1 2025
2025-03-31
Not filed-$51.7M-$54.4M$55.1M$50.9MNeeds four quarters10-Q 2026-11-05
Q4 2024
2024-12-31
Not filed-$43.4M-$39.2M$92.6M$50.7MNeeds four quarters10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-12-10
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-09

Source: SEC EDGAR submissions feed, 480 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.7%
1 month+4.9%
3 months-2.7%
Year to date-44.5%
1 year-1.0%
From 52-week high-49.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
TRAXFirst Tracks Biotherapeutics Inc. Ordinary Shares$46.56-1.15%$2.0B
HRMYHarmony Biosciences Holdings Inc.$32.96-2.37%$1.9B
MRVIMaravai LifeSciences Holdings Inc.$7.40-1.86%$1.9B
SEPNSepterna Inc.$41.67-2.18%$2.0B
TRVITrevi Therapeutics Inc.$13.29-2.64%$1.9B
ZBIOZenas BioPharma Inc.$27.93-0.29%$1.9B
SDGRSchrodinger Inc.$27.36-7.35%$2.1B
ETONEton Pharmaceuticals Inc.$63.88-0.08%$1.8B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier